Saturday 17 October 2026 Export QURE’s income statement to Excel — free account

uniQure N.V.

uniQure N.V.’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, down 40.6% from fiscal 2024. In the quarter to June 2026, revenue grew 11.0%, EPS fell 76.8%, free cash flow grew 27.7% and total debt fell 3.27%, each against the same quarter a year earlier.

21.72 0.80 −3.55%

Follow QURE

Alert me

Market cap: $1.6B
P/E: 0.0×
Fwd P/E: −7.7×
Dividend yield: —
F-score: 5/9
Altman Z: −0.80
Beneish M: −2.95
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 22.08

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	—	2	2	8	—	1	18	1	—	—	—

Insider Ownership 2.69%

Capital & Financial Ratios $m

Market Cap 1,560.00

Revenue 18.67

Net Income (252.21)

Free Cash Flow (161.45)

Net Debt (760.19)

Current Ratio 10.01

Debt/Equity 0.15

P/E ratio 0.00

Fwd P/E (7.70)

P/S ratio 77.06

P/B ratio 4.44

Past 5Y EPS Growth —

This Y EPS Growth (12.03%)

Next Y EPS Growth 22.13%

Next Y revenue growth 48.53%

Next 5Y EPS Growth 30.27%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 68.12%

10-year low 10-year high

P/B against its own 10 years 46.70%

10-year low 10-year high

EV/Sales against its own 10 years 57.06%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	618	368	623	810
Receivables	4	6	6	6
Inventory	12	—	—	—
Other	3	8	7	8
	652	390	656	834

	2023	2024	2025	Q'26
Payables	7	7	5	5
ST’ Debt	—	—	—	—
Other	28	—	13	24
	74	40	63	83

Compound Annual Growth %

	10y	5y	3y
Sales	4.29%	(15.57%)	(46.73%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	4.51%	(4.00%)	(25.24%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	4	6	—	—	—
’25	2	5	4	6	16
’24	8	11	2	5	27
’23	5	2	1	7	16
’22	2	0	1	103	106
’21	0	464	2	58	524
’20	0	2	2	34	38

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(38)	(29)	—	—	—
’25	(44)	(40)	(16)	(78)	(178)
’24	(61)	(33)	(37)	(53)	(183)
’23	(78)	(57)	39	(50)	(146)
’22	(26)	(16)	(49)	(55)	(145)
’21	(41)	416	(40)	(47)	288
’20	(33)	(30)	(35)	(37)	(135)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(38)	(29)	—	—	—
’25	(44)	(40)	(16)	(78)	(178)
’24	(63)	(33)	(37)	(53)	(186)
’23	(81)	(58)	37	(52)	(153)
’22	(30)	(20)	(53)	(60)	(163)
’21	(45)	414	(48)	(51)	271
’20	(36)	(32)	(37)	(40)	(144)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.85)	(1.22)	—	—	—
’25	(0.82)	(0.69)	(1.38)	(0.56)	(3.46)
’24	(1.36)	(1.16)	(0.91)	(1.50)	(4.92)
’23	(1.63)	(1.44)	(1.88)	(1.53)	(6.47)
’22	(1.00)	(0.84)	(1.02)	0.15	(2.71)
’21	(0.91)	8.51	(0.79)	0.17	7.04
’20	(0.63)	(0.96)	(1.21)	(0.01)	(2.81)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	5.45	4.72	16.77	26.94	34.38	19.50	12.52	5.49	3.73	7.76	Analyst estimates 2026–2028 Powerpack
	High	19.40	21.35	43.23	82.49	76.69	42.27	28.26	23.46	18.42	71.50
People
People	Employees	251	202	212	248	332	463	501	480	209	221
	Revenue/emp, $m	0.10	0.06	0.05	0.03	0.11	1.13	0.21	0.03	0.13	0.07
Income, $m
Income, $m	Revenue	25	13	11	7	38	524	106	16	27	16
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	96.86	13.98	32.42	89.53
	EBT	(72)	(79)	(83)	(124)	(141)	333	(128)	(307)	(237)	(193)
	EBT margin, %	(287.79)	(606.23)	(736.20)	(1,705.82)	(377.04)	63.51	(120.45)	(1,934.97)	(874.39)	(1,201.02)
	Net income	(73)	(79)	(83)	(124)	(125)	330	(127)	(308)	(240)	(199)
	Depreciation	6	8	12	7	11	7	9	12	13	15
Per share, $
Per share, $	Revenue	1.00	0.49	0.32	0.18	0.84	11.39	2.28	0.33	0.56	0.28
	Earnings	(2.93)	(2.94)	(2.34)	(3.11)	(2.81)	7.17	(2.71)	(6.47)	(4.92)	(3.46)
	Cash flow	(2.88)	(2.38)	(2.13)	(2.47)	(3.03)	6.26	(3.10)	(3.06)	(3.76)	(3.09)
	Capex	(0.69)	(0.21)	(0.12)	(0.17)	(0.21)	(0.38)	(0.38)	(0.15)	(0.07)	(0.01)
	Free cash flow	(3.57)	(2.59)	(2.25)	(2.63)	(3.25)	5.88	(3.48)	(3.21)	(3.83)	(3.10)
	Book value	2.54	3.31	5.04	8.08	5.49	12.96	10.19	4.36	(0.14)	3.46
	Shares, m	25	27	36	40	44	46	47	48	49	58
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	2.90	0.00	0.00	0.00	0.00
	P/S	5.86	41.50	91.03	393.68	42.83	1.82	9.59	20.85	31.68	85.48
	P/B	2.31	6.09	5.72	8.87	6.59	1.60	2.14	1.59	0.00	6.92
	EV/Sales	1.38	30.93	74.08	347.87	37.47	0.97	7.31	(11.21)	20.32	50.40
	EV/FCF	(0.39)	(5.80)	(10.41)	(24.05)	(9.74)	1.89	(4.72)	1.14	(2.93)	(4.49)
Cash, $m
Cash, $m	Operating cash flow	(72)	(64)	(76)	(99)	(135)	288	(145)	(146)	(183)	(178)
	Capex	(17)	(6)	(4)	(7)	(9)	(17)	(18)	(7)	(3)	0
	Free cash flow	(89)	(70)	(80)	(105)	(144)	271	(163)	(153)	(186)	(178)
Balance, $m
Balance, $m	Working capital	121	144	217	353	232	591	401	578	350	593
	Total debt	20	21	44	36	36	101	103	102	51	50
	Net debt	(112)	(139)	(191)	(342)	(209)	(455)	(250)	(516)	(316)	(573)
	Shareholders’ equity	64	89	180	323	244	596	476	208	(7)	199
Returns, %
Returns, %	ROA	(32.40)	(39.64)	(34.46)	(34.38)	(31.69)	57.34	(16.75)	(40.15)	(34.51)	(28.81)
	ROIC	0.00	0.00	0.00	0.00	(226.63)	138.19	(39.60)	0.00	0.00	0.00
	ROE	(76.61)	(103.61)	(61.94)	(49.42)	(44.10)	78.50	(23.66)	(90.24)	(238.46)	(207.10)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
OCUL Ocular Therapeutix, Inc.	$1.6B	— (loss-making)	— (loss-making)	+0.12% (above 0%: growing)	n/m	−25.35% (below 0%: shrinking)	85.08%	(609.34%)	Compare
NTLA Intellia Therapeutics, Inc.	$1.6B	— (loss-making)	— (loss-making)	−46.23% (below 0%: shrinking)	n/m	+15.05% (above 0%: growing)	100.00%	(1,472.25%)	Compare
STOK Stoke Therapeutics, Inc.	$1.6B	— (loss-making)	— (loss-making)	−32.51% (below 0%: shrinking)	n/m	−128.97% (below 0%: shrinking)	100.00%	(701.65%)	Compare
GPCR Structure Therapeutics Inc. Sponsored ADR	$1.6B	— (loss-making)	—	—	n/m	−119.15% (below 0%: shrinking)	0.00%	0.00%	Compare
QURE uniQure N.V.	$1.6B	— (loss-making)	— (loss-making)	+11.00% (above 0%: growing)	n/m	+27.66% (above 0%: growing)	94.01%	(893.73%)
KRSA Korsana Biosciences, Inc.	$1.5B	— (loss-making)	— (loss-making)	−43.24% (below 0%: shrinking)	n/m	−184.69% (below 0%: shrinking)	100.00%	0.00%	Compare
MAZE Maze Therapeutics, Inc.	$1.5B	— (loss-making)	—	—	n/m	+50.21% (above 0%: growing)	100.00%	0.00%	Compare
ABSI Absci Corporation	$1.5B	— (loss-making)	— (loss-making)	−46.37% (below 0%: shrinking)	n/m	−71.74% (below 0%: shrinking)	100.00%	(10,741.51%)	Compare
IMCR Immunocore Holdings PLC Sponsored ADR	$1.5B	— (loss-making)	208×	+18.34% (above 0%: growing)	n/m	−40.74% (below 0%: shrinking)	99.06%	(2.58%)	Compare
Median of peers	$1.6B	—	—	−37.88%	—	−56.24%	100.00%	(305.96%)

All 614 Biotechnology stocks →

uniQure N.V. (QURE) key facts

Concern: uniQure N.V.’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, down 40.6% from fiscal 2024.
uniQure N.V. (QURE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, QURE traded at $21.72, a market capitalization of $1.6 billion.
Return on equity was −207.1% and debt-to-equity 0.15.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −0.80 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.